

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: NEELAM et al.

Art Unit: 1642

Serial No. 09/778,963

Examiner: K. Canella

Filed: February 8, 2001

Atty. Docket: CL001112

For: ISOLATED HUMAN RAS-LIKE
PROTEINS, NUCLEIC ACID MOLECULES
ENCODING THESE HUMAN RAS-LIKE
PROTEINS, AND USES THEREOF

**Submission Of Substitute Sequence Listing
Under 37 CFR § 1.821(a)**

Assistant Commissioner for Patents
Washington, D.C. 20231

HAND CARRY

Sir:

In compliance with 37 C.F.R. § 1.821(a), applicants submit herewith a substitute Sequence Listing, including the paper copy (7 pages) of the substitute Sequence Listing and the computer readable copy of the substitute Sequence Listing. The substitute Sequence Listing includes no new matter.

The substitute Sequence Listing is identical to the Sequence Listing filed on May 8, 2001, except that SEQ ID NO:3 has been corrected by converting the amino acid sequence to the nucleotide sequence presented in Figure 3. In the Sequence Listing filed on May 8, 2001, SEQ ID NO:3 was unintentionally processed by the FastSeq software as a 1-letter protein code sequence rather than a nucleotide sequence and, consequently, each "A" was changed to "Ala", each "C" was changed to "Cys", each "G" was changed to "Gly", and each "T" was changed to "Thr". Note that the length of SEQ ID NO:3 is unchanged at 11,221 residues in length. No new matter is included in the Sequence Listing submitted herewith, since the correct nucleotide sequence of SEQ ID NO:3 was presented in Figure 3 of the application as originally filed and, furthermore, one can readily arrive at the correct sequence by converting each protein to it's corresponding nucleotide as indicated above.

RECEIVED
TECH CENTER 1600/2900
01 NOV 30 PM 2:39

The only other difference between the substitute Sequence Listing and the Sequence Listing submitted on May 8, 2001 is that the organism designation for SEQ ID NOS:1-4 has been changed from "Human" to "Homo sapiens" in the substitute Sequence Listing. This change does not constitute new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the substitute Sequence Listing and the computer readable copy of the substitute Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application complies with the Sequence Listing requirements and is now in condition for processing.

Respectfully submitted,
CELERA GENOMICS

Date: November 30, 2001

Celera Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3067
Fax: 240-453-3084

By: 
Justin D. Karjala, Reg No. 43,704